COSTS OF BENIGN PROSTATIC HYPERPLASIA TREATMENT IN MONTENEGRO
Abstract
Introduction/Aim. Benign prostatic hyperplasia (BPH) is one of the most frequent diseases in men older than 50 years, and it is closely linked to ageing process. Considering rising life expectancy, further increase in prevalence of BPH could be expected. The aim of our study was to analyze costs of treating patients with BPH in Montenegro, in order to estimate their impact on health budget.
Мethods. The BPH treatment costs were analyzed in a random sample of 47 male patients, 50 years of age or older, taken from the population of patients with BPH treated in Hospital Niksic, Montenegro, during year 2013. The patients were in one of the five health states: mild symptoms of BPH, moderate symptoms of BPH, severe symptoms of BPH, acute urinary retention , and transurethral resection of the prostate (TURP). Only direct medical costs were taken into account when calculating costs of each health state. The costs were calculated on the basis of utilization of services, drugs and materials, taken from the patients’ medical records, and utilization figures were multiplied with prices recognized by the Health Insurance Fund, Montenegro. Total number of patients with BPH in Montenegro was taken from the database of Institute for Public Health, Montenegro. The costs are expressed in euros (EUR).
Results. Average annual costs of treating a patient with certain BPH health state were: mild BPH - 266,63 ЕUR, moderate BPH - 343,26 EUR, severe BPH - 413,51 EUR, acute urinary retention - 493,93 ЕUR and TURP - 1.013,16 ЕUR. Total costs of treating all patients with BPH in Montenegro are 2.338.008,66 ЕUR; this amount makes 1,43% of total Montenegrian health budget. The largest part of the costs make medication acquisition costs, especially those spent for finasteride (196.341,11 ЕUR) and antimicrobials. According to the data generated by Montenegrian Drug Agency, annual turnover of all drugs indicated for treatment of BPH in 2011 was 595.948,74 ЕUR, and from this amount, 251.157,66 ЕUR was paid by Montenegrian Health Insurance Fund. During the period 2006 – 2011, number of patients with BPH increased for 370%, and the annual amount spent for BPH drugs increased for 373%.
Conclusion. Costs of treating BPH in Montenegro make significant percent of total healthcare costs, and there is trend of increase in costs due to constant increase in number of patients with BPH in Montenegro.
References
Morris S, Devlin N, Parkin D, Spencer A. Principles of economic evaluation in health care. In: Morris S, Devlin N, Parkin D, Spencer A,eds., Economic Analysis in Health Care (2nd ed.). Chichester: John Wiley & Sons, 2012:232-50.
Rice DP. Cost-of-illness studies: fact or fiction? Lancet. 1994;344:1519– 20.
Byford S, Torgerson DJ, Raftery J. Cost of illness studies. British Medical Journal 2000; 320:1335.
McVary KT, Roehrborn CG, Avins AL, et al.American Urological Association Guideline: Management of Benign Prostatic Hyperplasia (BPH). American Urological Association Education and research, Inc. 2010: 2-10.
Donovan JL, Kay HE, Peters TJ, et al. Using ICSQoL to measure the impact of lower urinary tract symptoms on quality of life: evidence from the ICS-“BPH” study. British Journal of Urology 1997; 80:712– 21.
Oelke M, Bachmann A, Descazeaud A, et al. Guidelines on the Management of Male Lower Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO) European Association of Urology Guidelines 2012.
Chute CG. The prevalence of prostatism: a population based survey of urinary symptoms. Journal of Urology1993;150:85-9.
Arrighi HM, Metter EJ, Guess HA, Fozzard JL. Natural History of benign prostatic hyperplasia and risk of prostatectomy. The Baltimore Longitudinal Study of Aging. Journal of Urology 1991; 38(1): 4-8.
Centers for Disease Control and Prevention: Trends in aging-United States and worldwide. MMWR – Morbidity and Mortalilti Weekly Report 2003; 52:101– 4, 106.
Zavod za statistiku Crne Gore - Monstat. Dostupno na: http://www.monstat.org/cg/page.php?id=57&pageid=57; Pristup: 08.02.2014.
Bahia LR, Araujo DV, Pepe C, Trindade M, Camargo CM, Javaroni V. Cost-effectiveness analysis of medical treatment of benign prostatic hyperplasia in the Brazilian public health system. International Brazilian Journal of Urology 2012; 38(5): 595-605.
Institut za javno zdravlje Crne Gore (IJZCG). Dostupno na: http://www.ijzcg.me/2013/12/statisticki-godi-snjak-2011-godina/. Pristup: 26.11.2014.
Lee EH, Chun KH, Lee Y. Benign prostatic hyperplasia in community-dwelling elderly in Korea. Journal of Korean Academyof Nursing 2005; 35(8):1508-13.
Lepor H, Machi G. Comparison of AUA symptom index in unselected males and females between fifty-five and seventy-nine years of age. Urology 1993; 42:36-9.
Taylor BC, Wilt TJ, Fink HA, et al. Prevalence, severity, and health correlates of lower urinary tract symptoms among older men: the MrOS study. Urology 2006; 68: 804.
Kaplan SA, Olsson CA, Te AE. The American Urological Association symptom score in the evaluation of men with lower urinary tract symptoms: at 2 years of followup, does it work? Journal of Urology 1996;155(6):1971-4.
Roehrborn CG. The Epidemiology of Acute Urinary Retention in Benign Prostatic Hyperplasia. Urology 2001; 3(4):187– 92.
Madersbacher S, Lackner J, Brossner C, et al. Reoperation, myocardial infarction and mortality after transurethral and open prostatectomy: a nation-wide, long-term ana-lysis of 23,123 cases. European Urology 2005;47:499–504.
Izvještaj o radu I poslovanju Fonda za zdravstveno osiguranje Crne Gore za 2011. Dostupno na: http://fzocg.me/docs/807/izvjestaj_o_radu_i_poslovanju_fonda_za_zdravstveno_osiguranje_crne_gore_za_2011.godinu.pdf. Pristup 27.11.2014.
ATC Index with DDDs. WHO Collaborating Centre of Drug Statistics Methodology. Oslo: Norwegian Institute of Public Health 2014. Dostupno na: http://pharmacoepi.org/pub/5f279d2a-a2ac-46b8-7da5-e4dcb4de5830.Pristup 01.12.2014.
Issa MM, Fenter TC, Black L, Grogg AL, Kruep EJ. An assessment of the diagnosed prevalence of diseases in men 50 years of age or older. American Journal of Managed Care 2006;12(4): 83.
Patel ND, Parsons JK. Epidemiology and etiology of benign prostatic hyperplasia and bladder outlet obstruction. Indian Journal of Urology 2014;30(2):170-6.
Drummond MF, McGuire AJ, Black NA, Petticrew M, McPherson CK. Economic burden of treating benign prostatic hyperplasia in the United Kingdom. British Journal of Urology 1993; 71(3):290- 6.
Treatment options for benign prostatic hyperplasia (BPH). A report by the Australian Health Technology Advisory Committee, 1994. Dostupno na: https://www.nhmrc.gov.au/_files_nhmrc/publications/attachments/m1.pdf. Pristup 02.12.2014.
Ahlstrand C, Carlsson P, Jönsson B. Estimated total costs of treating benign prostatic hyperplasia in Sweden. Scandinavian Journal of Urology and Nephrology 1995; 29:57–63.
Lee EH, Chun KH, Lee Y. Benign prostatic hyperplasia in community-dwelling elderly in Korea. Journal of Korean Academy of Nursing 2005; 35(8):1508-13.
Terai A, Kakehi Y, Terachi T, Ogawa O. National trend of management of benign prostatic hyperplasia in Japan during 1990s: Analysis of national health statistics. Hinyokika Kiyo 2000; 46(8):537- 44.
Suaid HJ, Gonçalves MA, Junior AAR, Cunha JP, ColognaAJ, Martins ACP 2003. Estimated costs of treatmentof benign prostate hyperplasia in Brazil. International Brazilian Journal of Urology 2003; 29:234-237.
Hrvatska agencija za lijekove i medicinske proizvode - Halmed. Dostupno na: http://www.halmed.hr/? ln=hr&w=publikacije&d=potrosnja_lijekova. Pristup 07.03.2015.
Promet i potrošnja gotovih lekova za humanu upotrebu u Republici Srbiji u 2004. i 2005. godini. Agencija za lekove i medicinska sredstva Srbije. Beograd 2006.
Promet i potrošnja gotovih lekova za humanu upotrebu u Republici Srbiji u 2009. godini. Agencija za lekove i medicinska sredstva Srbije. Beograd 2010.
Javna agencija Republike slovenije za zdravila in medicinske pripomočke. Seznam veljavnih cen zdravil. Dostupno na: http://www.jazmp.si/fileadmin/datoteke/ seznami/SFE/Cene/cene_20141015.pdf. Pristup 07.03.2015.
Hrvatski Zavod za zdravstveno osiguranje. Osnovna lista lijekova. Dostupno na: http://www.hzzo.hr/ zdravstveni-sustav-rh/trazilica-za-lijekove-s-vazecih-lista. Pristup 07.03.2015.
Ministarstvo zdravlja Republike Srbije. Spisak cena lekova. Dostupno na: http://www.zdravlje.gov.rs/ downloads/2013/Jun/Jun2013SpisakCenaLekova.pdf. Pristup 06.03.2015.
Spire Harpenden Hospital. Dostupno na: http://www.spirehealthcare.com/harpenden/our-facilities-treatments-and-consultants/our-treatments/prostate-surgery-turp/; Pristup 13.05.2014.
British National Formulary 66, September 2013-March 2014; 396- 97.
Codra Medical. Dostupno na: http://www.codrahospital.com. Pristup 13.05.2014.